You should seek prompt medical advice if you are currently using unlicensed peptides and experience any of the following: Persistent nausea, vomiting, or severe abdominal pain (which may indicate pancreatitis) Unexplained changes in heart rate or palpitations Symptoms of hypoglycaemia , such as shakiness, sweating, confusion, or dizziness Injection site redness, swelling, or signs of infection Unusual lumps, swelling in the neck, or difficulty swallowing (which may indicate thyroid changes) Mood changes, anxiety, or psychological distress related to body image or supplement use For urgent medical advice, contact NHS 111 (online at 111.nhs.uk or by telephone)
Most weight loss begins after reaching higher doses, which takes about 16 weeks, as semaglutide is gradually increased to reduce side effects
In obesity trials, retatrutide has produced average weight loss of up to 24.2% at 48 weeks , 28.7% at 68 weeks , and 28.3% at 80 weeks , depending on the trial, dose and study population
Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement
constipation, reflux, or intermittent nausea may continue Persistent or progressive symptoms rather than gradual improvement After month 3 Symptoms may remain mild or infrequent at a tolerated regimen New severe symptoms should not automatically be blamed on the medication The most important pattern is not simply "week 1 is bad and month 3 is good." A more accurate pattern is initiation, adaptation, possible symptom flare during dose escalation, and reassessment based on tolerability
We may adjust your treatment plan or guide to help you feel more comfortable while continuing your weight loss journey safely and effectively
